Relationship between β1-AA and AT1-AA and Cardiac Function in Patients with Hypertension Complicated with Left

Liang Wang1, Xue-Bai Lv2, Yu-Ting Yuan1

  • 1Department of Cardiology, Peking University International Hospital, Beijing 102206, China.

Cardiovascular Therapeutics
|December 21, 2023
PubMed

Insights

Autoantibodies against the β1 adrenergic receptor and angiotensin II type-1 receptor are independent risk factors for left ventricular diastolic dysfunction in hypertensive patients. These autoantibodies show predictive value, with combined detection offering the highest diagnostic accuracy.

Area of Science:

  • Cardiology
  • Immunology
  • Hypertension Research

Background:

  • Hypertension frequently complicates with left ventricular diastolic dysfunction (LVDD).
  • Autoantibodies, including β1 adrenergic receptor autoantibodies (β1-AA) and angiotensin II type-1 receptor autoantibodies (AT1-AA), are implicated in cardiovascular diseases.
  • The specific role of these autoantibodies in LVDD among hypertensive patients requires further elucidation.

Purpose of the Study:

  • To investigate the association between β1-AA and AT1-AA and cardiac function in hypertensive patients with LVDD.
  • To evaluate the diagnostic efficacy of β1-AA and AT1-AA as early markers for LVDD in essential hypertension.

Main Methods:

  • A cohort of 120 essential hypertension patients (untreated) were divided into LVDD (65 cases) and normal diastolic groups (55 cases).
  • Cardiac parameters, β1-AA, and AT1-AA levels were compared between groups.
  • Logistic regression analysis identified independent risk factors for LVDD; diagnostic efficacy was assessed using receiver operating characteristic (ROC) curves.

Main Results:

  • The LVDD group exhibited significantly higher levels of β1-AA and AT1-AA compared to the normal group (P < 0.05).
  • Multivariate analysis confirmed β1-AA (OR=1.96) and AT1-AA (OR=2.02) as independent risk factors for LVDD.
  • The combined detection of β1-AA and AT1-AA demonstrated a high diagnostic value for LVDD (AUC=0.942).

Conclusions:

  • Elevated levels of β1-AA and AT1-AA are associated with LVDD in essential hypertension.
  • Both β1-AA and AT1-AA serve as valuable early diagnostic markers for LVDD in hypertensive patients.
  • Combined assessment of these autoantibodies enhances diagnostic accuracy for LVDD.
Abstract

Related Concept Videos

Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
450
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Antihypertensive Drugs: Types of &#946;-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
688
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
394